Uncategorized

AlzeCure gets Presentation Accepted on Disease-Modifying Effects of ACD856 at Alzheimer’s Conference

AlzeCure Pharma announced that an abstract with preclinical data on NeuroRestore ACD856 demonstrating its potential disease-modifying effects has been accepted for presentation at the annual Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, which this year is being held in Boston on October 24-27.

AlzeCure gets Presentation Accepted on Disease-Modifying Effects of ACD856 at Alzheimer’s Conference Read More »

Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch® Prostate Screening Blood Test to Men With Prostate Cancer Risk

Oxford BioDynamics, Plc. announced validation of its EpiSwitch Prostate Screening blood test in its US clinical laboratory, resulting in the immediate access to its highly accurate PSE test to men with prostate cancer risk.

Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch® Prostate Screening Blood Test to Men With Prostate Cancer Risk Read More »

Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its financial results for the period ended June 30, 2023 and provided a corporate update.

Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update Read More »

Sensorion Announces the Availability of Its Financial Report for the 1st Half of 2023

Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, Sensorion announces the availability of its 1st Half 2023 Financial Report to the public and filed with the Autorité des marchés financiers.

Sensorion Announces the Availability of Its Financial Report for the 1st Half of 2023 Read More »

Scroll to Top